Reproducibility of preclinical data: one man's poison is another man's meat
Journal Title: Advances in Precision Medicine - Year 2016, Vol 1, Issue 2
Abstract
Limited reproducibility of preclinical data is increasingly discussed in the literature. Failure of drug development programs due to lack of clinical efficacy is also of growing concern. The two phenomena may share an important root cause — a lack of robustness in preclinical research. Such a lack of robustness can be a relevant cause of failure in translating preclinical findings into clinical efficacy and hence attrition, and exaggerated cost in drug development. Apart from the study design and data analysis factors (e.g., insufficient sample sizes, failure to implement blinding, and randomization), heterogeneity among experimental models (e.g., animal strains) and the conditions of the study used between different laboratories is a major contributor to the lacking of robustness of research findings. The flipside of this coin is that the understanding of the causes of heterogeneity across experimental models may lead to the identification of relevant factors for defining the responder populations. Thus, this heterogeneity within preclinical findings could be an asset, rather than an obstacle, for precision medicine. To enable this paradigm shift, several steps need to be taken to identify conditions under which drugs do not work. An improved granularity in the reporting of preclinical studies is central among them (i.e., details about the study design, experimental conditions, quality of tools and reagents, validation of assay conditions, etc.). These actions need to be discussed jointly by the research communities interested in preclinical data robustness and precision medicine. Thus, we propose that a lack of robustness due to the heterogeneity across models and conditions of the study is not necessarily a liability for biomedical research but can be transformed into an asset of precision medicine.
Authors and Affiliations
Anton Bespalov, Christoph H. Emmerich, Björn Gerlach and Martin C. Michel
Keywords
Related Articles
- EP ID EP679269
- DOI -
- Views 170
- Downloads 0
Genomics Vault: A framework for precision medicine data management
A mixture of fumaric acid esters (FAEs) is approved for the oral therapy of psoriasis. However, for a long time the active ingredient of this mixture was unknown. We reviewed the in vitro data available for the different...
The research data reproducibility problem solicits a 21st century solution
Reproducibility is a hallmark of scientific efforts. Estimates indicate that lack of reproducibility of data ranges from 50% to 90% among published research reports. The inability to reproduce major findings of published...
The SMART healthcare solution
Substitutable Medical Apps Reusable Technologies (SMART®) on Fast Healthcare Interoperability Resources (FHIR) is an open, standards platform that allows third parties to build health applications that interact with elec...
Collaboration for success: the value of strategic collaborations for precision medicine and biomarker discovery
Precision medicine aims to provide the precise treatment for the patient with the right dose at the right point of time. Biomarkers (BM) are vital for the identification of patients who would benefit the most from indivi...
Reproducibility of preclinical data: one man's poison is another man's meat
Limited reproducibility of preclinical data is increasingly discussed in the literature. Failure of drug development programs due to lack of clinical efficacy is also of growing concern. The two phenomena may share an im...